158 related articles for article (PubMed ID: 35482532)
1. Efficacy and safety of avacopan in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: A subanalysis of a randomized Phase 3 study.
Harigai M; Kaname S; Tamura N; Dobashi H; Kubono S; Yoshida T
Mod Rheumatol; 2023 Mar; 33(2):338-345. PubMed ID: 35482532
[TBL] [Abstract][Full Text] [Related]
2. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial.
Strand V; Jayne DRW; Horomanski A; Yue H; Bekker P; Merkel PA;
Lancet Rheumatol; 2023 Aug; 5(8):e451-e460. PubMed ID: 38251577
[TBL] [Abstract][Full Text] [Related]
3. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Harigai M; Takada H
Mod Rheumatol; 2022 Apr; 32(3):475-483. PubMed ID: 34984461
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid Toxicity Index scores by domain in patients with antineutrophil cytoplasmic antibody-associated vasculitis treated with avacopan versus standard prednisone taper: post-hoc analysis of data from the ADVOCATE trial.
Patel NJ; Jayne DRW; Merkel PA; Bekker P; Zhang Y; Yue H; Stone JH
Lancet Rheumatol; 2023 Mar; 5(3):e130-e138. PubMed ID: 38251609
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
Geetha D; Dua A; Yue H; Springer J; Salvarani C; Jayne D; Merkel P;
Ann Rheum Dis; 2024 Jan; 83(2):223-232. PubMed ID: 37979959
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological and clinical profiles of avacopan (TAVNEOS
Maruyama Y; Yoshida T; Maruyama I
Nihon Yakurigaku Zasshi; 2023 Sep; 158(5):399-407. PubMed ID: 37460300
[TBL] [Abstract][Full Text] [Related]
7. Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW; Merkel PA; Schall TJ; Bekker P;
N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
[TBL] [Abstract][Full Text] [Related]
8. Journal Club Review of "Avacopan for the Treatment of ANCA-Associated Vasculitis".
Soulsby WD
ACR Open Rheumatol; 2022 Jul; 4(7):558-561. PubMed ID: 35167187
[TBL] [Abstract][Full Text] [Related]
9. How the Availability of Anti-C5a Agents Could Change the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Roccatello D; Fenoglio R; Oddone V; Sciascia S
Kidney Blood Press Res; 2022; 47(8):506-513. PubMed ID: 35665698
[TBL] [Abstract][Full Text] [Related]
10. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
[TBL] [Abstract][Full Text] [Related]
11. Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Alihosseini C; Kopelman H; Zaino M; Feldman SR
Ann Pharmacother; 2023 Dec; 57(12):1449-1454. PubMed ID: 36975183
[TBL] [Abstract][Full Text] [Related]
12. Seasonal Influence on Development of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Conducted at Multiple Institutions in Japan (J-CANVAS).
Yoshida Y; Nakamoto N; Oka N; Kidoguchi G; Hosokawa Y; Araki K; Ishitoku M; Watanabe H; Sugimoto T; Mokuda S; Kida T; Yajima N; Omura S; Nakagomi D; Abe Y; Kadoya M; Takizawa N; Nomura A; Kukida Y; Kondo N; Yamano Y; Yanagida T; Endo K; Matsui K; Takeuchi T; Ichinose K; Kato M; Yanai R; Matsuo Y; Shimojima Y; Nishioka R; Okazaki R; Takata T; Ito T; Moriyama M; Takatani A; Miyawaki Y; Ito-Ihara T; Kawaguchi T; Kawahito Y; Hirata S
J Rheumatol; 2023 Sep; 50(9):1152-1158. PubMed ID: 37263656
[TBL] [Abstract][Full Text] [Related]
13. Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan.
Alvarez L; Kambham N; Su R
J Nephrol; 2023 Nov; 36(8):2365-2370. PubMed ID: 37036661
[TBL] [Abstract][Full Text] [Related]
14. Nation-wide survey of the treatment trend of microscopic polyangiitis and granulomatosis with polyangiitis in Japan using the Japanese Ministry of Health, Labour and Welfare Database.
Nagasaka K; Kaname S; Amano K; Kato M; Katsumata Y; Komagata Y; Sada KE; Tanaka E; Tamura N; Dobashi H; Nanki T; Harabuchi Y; Bando M; Homma S; Wada T; Harigai M
Mod Rheumatol; 2022 Aug; 32(5):915-922. PubMed ID: 34918136
[TBL] [Abstract][Full Text] [Related]
15. Gradual increase of avacopan dose with concomitant ursodeoxycholic acid use may help avoid the risk of C5a receptor inhibitor-induced liver injury in antineutrophil cytoplasmic antibody-associated vasculitis.
Kataoka H; Tomita T; Nakanowatari M; Kondo M; Mukai M
Mod Rheumatol Case Rep; 2023 Jun; 7(2):444-447. PubMed ID: 36972244
[TBL] [Abstract][Full Text] [Related]
16. CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum.
Turgeon D; Bakowsky V; Baldwin C; Cabral DA; Clements-Baker M; Clifford A; Cohen Tervaert JW; Dehghan N; Ennis D; Famorca L; Fifi-Mah A; Girard LP; Lefebvre F; Liang P; Makhzoum JP; Massicotte-Azarniouch D; Mendel A; Milman N; Reich HN; Robinson DB; Ross C; Rumsey DG; Soowamber M; Towheed TE; Trudeau J; Twilt M; Yacyshyn E; Yardimci GK; Khalidi N; Barra L; Pagnoux C
Rheumatology (Oxford); 2023 Aug; 62(8):2646-2651. PubMed ID: 36805625
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
[TBL] [Abstract][Full Text] [Related]
18. Rationale of concomitant cyclophosphamide for remission-induction in patients with antineutrophil cytoplasmic antibody-associated vasculitis: A propensity score-matched analysis of two nationwide prospective cohort studies.
Watanabe H; Sada KE; Matsumoto Y; Harigai M; Amano K; Fujimoto S; Dobashi H; Yuzawa Y; Yamagata K; Muso E; Arimura Y; Makino H
Mod Rheumatol; 2021 Jan; 31(1):205-213. PubMed ID: 31859544
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytopenia during avacopan administration: A case report.
Morimoto N; Mori T; Shioji S; Watanabe H; Sakai K; Mori K; Yamamura A; Hanioka A; Akagi Y; Fujiki T; Mandai S; Mori Y; Ando F; Susa K; Iimori S; Naito S; Sohara E; Uchida S
Int J Rheum Dis; 2023 Aug; 26(8):1603-1607. PubMed ID: 36880594
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Ministry of Health, Labour and Welfare diagnostic criteria for antineutrophil cytoplasmic antibody-associated vasculitis compared to ACR/EULAR 2022 classification criteria.
Sada KE; Nagasaka K; Kaname S; Higuchi T; Furuta S; Nanki T; Tsuboi N; Amano K; Dobashi H; Hiromura K; Bando M; Wada T; Arimura Y; Makino H; Harigai M
Mod Rheumatol; 2024 Mar; 34(3):551-558. PubMed ID: 37279574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
